Sarepta Therapeutics Inc Stock Price, News & Analysis

Sarepta Therapeutics (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, announced its senior management will participate in a fireside chat at the BofA Securities Health Care Conference. The event will take place at the Encore Hotel in Las Vegas on May 14, 2025, at 8:40 a.m. PT/11:40 a.m. ET.

The presentation will be available via webcast on Sarepta's investor relations website and will remain archived for 90 days. The company maintains leadership positions in Duchenne muscular dystrophy and limb-girdle muscular dystrophies, while developing a portfolio focused on muscle, central nervous system, and cardiac diseases.

Sarepta Therapeutics (SRPT) reported Q1 2025 financial results with total revenues of $744.9M, up 80% year-over-year. Net product revenues reached $611.5M, a 70% increase, with ELEVIDYS contributing $375.0M (180% growth) and PMO franchise at $236.5M. However, facing headwinds, Sarepta revised its 2025 revenue guidance down to $2.3-2.6B from $2.9-3.1B. The company reported a GAAP net loss of $447.5M. The quarter saw significant pipeline progress in limb-girdle muscular dystrophy programs, including advancement in SRP-9005 (LGMD2C/R5), completed enrollment in SRP-9004 (LGMD2D/R3) study, and completion of EMERGENE phase 3 trial for SRP-9003. Sarepta closed a global licensing agreement with Arrowhead Pharmaceuticals for multiple clinical and preclinical programs in muscle, CNS, and rare pulmonary disorders.

Cash position stood at $647.5M as of March 31, 2025, down from $1.5B at year-end 2024.

Sarepta Therapeutics (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, has scheduled its first quarter 2025 financial results announcement. The results will be released after the Nasdaq Global Market closes on Tuesday, May 6, 2025, followed by a conference call at 4:30 p.m. E.T. to discuss the quarterly performance.

The event will be accessible through a live webcast on the investor relations section of Sarepta's website, with a replay available for one year. Phone participants must register online to receive dial-in details and a personal PIN for accessing the event.

Sarepta Therapeutics (NASDAQ:SRPT) announced significant progress in its limb-girdle muscular dystrophy (LGMD) pipeline programs. The FDA has cleared the company to proceed with dosing in Study SRP-9005-101 (COMPASS) for LGMD2C/R5, marking their fourth LGMD program to enter clinical trials.

The company has completed enrollment and dosing in Study SRP-9004-102 (DISCOVERY) for LGMD2D/R3. Additionally, enrollment and dosing are complete in the phase 3 EMERGENE trial of SRP-9003 for LGMD2E/R4, with data expected by mid-2025. The FDA has confirmed eligibility for accelerated approval, and Sarepta plans to submit a Biologics License Application in the second half of 2025.

These developments are significant as there are currently no disease-modifying treatments approved for any LGMD subtype. Sarepta's LGMD pipeline covers subtypes that represent over 70% of known LGMD cases.

Sarepta Therapeutics (NASDAQ:SRPT) announced a temporary halt in recruitment and dosing for certain clinical studies of ELEVIDYS, their approved gene therapy for Duchenne muscular dystrophy. This follows a safety update on acute liver failure from March 18.

The independent data monitoring committee (DMC) reviewed the adverse event on April 3 and concluded that the overall benefit-risk profile remains favorable to continue dosing. The affected studies include SRP-9001-302 (ENVOL), SRP-9001-303 (ENVISION), and SRP-9001-104.

Sarepta and Roche will submit their response to EU regulators within a week. The company maintains that monitoring and data collection for already-enrolled participants continues, and they do not anticipate material impact on study timelines.

Sarepta Therapeutics (NASDAQ:SRPT) has announced equity awards granted to 39 new employees hired in Q1 2025 under its 2024 Employment Commencement Incentive Plan. The grants, approved by the Compensation Committee and compliant with Nasdaq Listing Rule 5635(c)(4), include:

• 31,344 stock options with an exercise price of $63.82 per share
• 77,442 restricted stock units (RSUs)

The stock options will vest over four years, with 25% vesting after one year and the remaining vesting monthly at 1/48th. RSUs will vest annually at 25% over four years. Both are subject to continued employment.

Sarepta Therapeutics (NASDAQ:SRPT) has launched the 8th Annual Route 79 Duchenne Scholarship Program for the 2025-2026 academic year. The program will award academic scholarships of up to $5,000 to as many as 20 individuals living with Duchenne muscular dystrophy and 5 siblings of those affected.

Applications will be accepted until May 30, 2025, with recipients notified before August 2025. Eligible applicants must be accepted to or enrolled in an accredited U.S. college, university, or trade school. The selection process is conducted by an independent committee, with awards distributed for fall 2025 enrollment.

The scholarship program, named after the 79 exons of the dystrophin gene, allows recipients to receive awards up to four times. Selection is made without consideration of whether applicants use Sarepta products or therapies.

Sarepta Therapeutics (NASDAQ:SRPT) reported strong Q4 2024 financial results with net product revenues of $638.2 million, up 75% year-over-year. ELEVIDYS, their gene therapy for Duchenne muscular dystrophy, generated $384.2 million in quarterly revenue, with additional $4.9 million in royalties from Roche sales.

The company achieved GAAP net income of $159.0 million and non-GAAP net income of $206.0 million in Q4 2024. For 2025, Sarepta projects net product revenue guidance of $2.9-3.1 billion, representing 70% year-over-year growth.

Key developments include establishing a $600 million credit facility, positive EMBARK study results for ELEVIDYS, and a global licensing agreement with Arrowhead Pharmaceuticals for siRNA programs. The company completed enrollment in the EMERGENE Phase 3 trial for LGMD2E/R4 gene therapy, with data expected in H1 2025.

Sarepta Therapeutics (NASDAQ:SRPT) has secured a $600 million senior secured revolving credit facility through a bank syndicate led by JPMorgan Chase Bank. This non-dilutive financing arrangement enhances the company's financial flexibility while complementing its existing strong balance sheet.

The credit facility, which received oversubscribed demand, demonstrates lenders' confidence in Sarepta's future cash and EBITDA growth trajectory. The syndicate includes major financial institutions such as Barclays Bank, Citizens Bank, Goldman Sachs USA, Morgan Stanley, Royal Bank of Canada, Fifth Third Bank, UBS AG, and Bank of America.

The facility is designed to provide contingent liquidity as the company executes its strategic plan toward achieving its Sarepta 2030 objectives.